BioHealth Innovation, Inc. (BHI) is pleased to announce the appointment of Dr. Nilay Shah to its Board of Directors. A physician–executive with more than 20 years of experience in global clinical development and commercial strategy, Dr. Shah brings deep expertise in advancing innovative therapies from early development through regulatory approval and market entry.
Dr. Shah currently serves as Senior Vice President and Global Head of Ophthalmology at Emmes, where he leads the company’s fastest-growing therapeutic division and serves on the Executive Management Committee. Over the course of his tenure, he has helped scale the organization into a global CRO serving biotech innovators across North America, Europe, Latin America, and Asia. His experience spans Phase I through Phase III trials, FDA and EMA engagement, pharmacovigilance, and strategic alliances with emerging and growth-stage life sciences companies.
Throughout his career, Dr. Shah has served as a Medical Monitor for various studies and also has directed complex, multi-national clinical programs, including global trials supporting market authorization of novel biologics and the first autonomous AI-based diagnostic system approved by the FDA for the detection of diabetic retinopathy. He has also built and led high-performing cross-functional teams, strengthened commercial strategy, and partnered closely with venture-backed companies navigating regulatory and operational milestones.
Beyond his executive leadership, Dr. Shah has played an active role in Maryland’s innovation ecosystem. He serves as an advisor and reviewer for multiple TEDCO venture programs and is a Board Member of the Baltimore Innovation Initiative, where he supports early-stage founders in clinical strategy, regulatory planning, and commercialization.
“Nilay brings a rare combination of physician insight, global clinical operations leadership, and commercial acumen,” said BHI President and CEO, Rich Bendis. “He understands what it takes to move a therapy from concept to approval, and he has done it at scale. As we continue to support entrepreneurs and growing companies across the BioHealth Capital Region and beyond, his experience will strengthen our ability to guide companies through critical development and regulatory inflection points.”
“I am honored to join the Board of BioHealth Innovation at a pivotal time for the BioHealth Capital Region,” said Nilay C. Shah, MBBS (MD), Senior Vice President and Global Head of Ophthalmology at Emmes. “We are witnessing a powerful convergence of breakthrough science, artificial intelligence, and precision medicine, but innovation only matters if it translates into approved and accessible therapies. Throughout my career in global clinical development, I have seen how early strategic guidance and disciplined execution accelerate that journey. BioHealth Innovation uniquely bridges scientific innovation and commercialization, and I look forward to supporting entrepreneurs as they navigate critical regulatory and development milestones to bring transformative therapies to patients faster.”
Dr. Shah’s appointment reflects BHI’s continued focus on assembling a board with hands-on experience in therapeutic development, regulatory strategy, venture engagement, and global operations. His perspective will support the organization’s mission to accelerate commercialization, mentor emerging companies, and expand the region’s leadership in biohealth innovation.